Christopher Lieu, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz Medical Campus

Christopher Lieu, University of Colorado Anschutz Medical Campus

Caption

Christopher Lieu, MD, and University of Colorado Cancer Center phase I clinical trials team show strong activity but challenging 'pharmacokinetics' of the new drug, TAK-733.

Credit

CU Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.